Abbott Plans to Spin Off $8.5 Billion Nutrition Business by End of 2027

Abbott said on October 21, 2026, that it plans to separate its global Nutrition business into an independent, publicly traded company through a tax-free distribution of shares to Abbott shareholders. The new company would have approximately $8.5 billion in annual sales, 16,000 employees and brands including Similac, PediaSure, Pedialyte, Glucerna and Ensure, while Abbott would retain approximately $42 billion in sales and its medical device, diagnostics and established medicines businesses. The separation is expected by the end of 2027, subject to regulatory approvals and other conditions, and Abbott said it will not change its 2026 guidance or the 2027 guidance it plans to issue in January.